Showing results (131-140 of 148) with videos related to
Sort By:
Pageof 15
Blood Advances|June 23, 2020
Cotargeting BCL-2 and MCL-1 in high-risk B-ALLDonia M Moujalled, Diane T Hanna, Soroor Hediyeh-Zadeh, et al.Cancer Discovery|October 25, 2023
Loss-of-Function but Not Gain-of-Function Properties of Mutant TP53 Are Critical for the Proliferation, Survival, and Metastasis of a Broad Range of Cancer CellsZilu Wang, Matteo Burigotto, Sabrina Ghetti, et al.Nature Medicine|November 21, 2018
Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphomaRishu Agarwal, Yih-Chih Chan, Constantine S Tam, et al.Blood|June 19, 2013
Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcriptionDaniel Thomas, Jason A Powell, Francois Vergez, et al.Blood|October 29, 2024
Venetoclax dose escalation rapidly activates a BAFF/BCL-2 survival axis in chronic lymphocytic leukemiaMeng-Xiao Luo, Tania Tan, Marie Trussart, et al.Cancer Discovery|December 4, 2021
Pharmacologic Reduction of Mitochondrial Iron Triggers a Noncanonical BAX/BAK-Dependent Cell DeathSylvain Garciaz, Andrew A Guirguis, Sebastian Müller, et al.Nature Communications|March 18, 2015
A RIPK2 inhibitor delays NOD signalling events yet prevents inflammatory cytokine productionUeli Nachbur, Che A Stafford, Aleksandra Bankovacki, et al.Immunity|April 10, 2012
The dendritic cell receptor Clec9A binds damaged cells via exposed actin filamentsJian-Guo Zhang, Peter E Czabotar, Antonia N Policheni, et al.ACS Medicinal Chemistry Letters|June 20, 2014
Structure-Guided Rescaffolding of Selective Antagonists of BCL-XLMichael F T Koehler, Philippe Bergeron, Edna F Choo, et al.Nature Communications|November 28, 2018
VDAC2 enables BAX to mediate apoptosis and limit tumor developmentHui San Chin, Mark X Li, Iris K L Tan, et al.Pageof 15